Table 5 |
||||||
|
Univariate and multivariate Cox analyses in The Netherlands Cancer Institute data set (n = 295) |
||||||
|
Factor |
Univariate metastasis-free survival |
Multivariate metastasis-free survivala |
||||
|
|
||||||
|
Hazard ratio (95% confidence interval) |
P value |
With 70-gene signature |
Without 70-gene signature |
|||
|
|
||||||
|
Hazard ratio (95% confidence interval) |
P value |
Hazard ratio (95% confidence interval) |
P value |
|||
|
|
||||||
|
E2F1 (>p30 versus ≤ p30) |
5.09 (2.65–9.78) |
<0.001 |
3.76 (1.90–7.45) |
<0.001 |
2.47 (1.20–5.10) |
0.014 |
|
Grade (3 versus 1 + 2) |
2.38 (1.60–3.52) |
<0.001 |
1.28 (0.82–2.00) |
0.277 |
1.02 (0.65–1.60) |
0.931 |
|
Estrogen receptor status (positive versus negative) |
0.54 (0.36–0.83) |
0.005 |
0.99 (0.61–1.59) |
0.956 |
1.11 (0.70–1.78) |
0.658 |
|
ERBB2 status (positive versus negative) |
1.61 (1.01–2.57) |
0.045 |
1.35 (0.82–2.21) |
0.234 |
1.28 (0.78–2.09) |
0.330 |
|
pN (>3 nodes versus ≤ 3 nodes) |
2.20 (1.37–3.53) |
0.001 |
2.35(1.32–4.21) |
0.004 |
2.69 (1.47–4.91) |
0.001 |
|
Size (>2 cm versus ≤ 2 cm) |
2.08 (1.39–3.10) |
<0.001 |
1.70 (1.12–2.58) |
0.013 |
1.73 (1.14–2.62) |
0.010 |
|
Age (≤ 40 years versus >40 years) |
0.50 (0.33–0.75) |
0.001 |
0.59 (0.38–0.89) |
0.013 |
0.67 (0.43–1.02) |
0.063 |
|
Chemotherapy |
0.79 (0.52–1.19) |
0.254 |
0.61 (0.38–1.00) |
0.051 |
0.55 (0.33–0.91) |
0.020 |
|
Hormone therapy |
0.58 (0.28–1.19) |
0.139 |
0.60 (0.28–1.27) |
0.181 |
0.58 (0.27–1.23) |
0.157 |
|
70-gene signature (poor versus good prognosis) |
4.55 (2.67–7.77) |
<0.001 |
Not included |
Not included |
2.78 (1.49–5.21) |
0.001 |
|
|
||||||
|
aMultivariate metastasis-free survival calculated once with and once without the 70-gene signature. |
||||||
|
Vuaroqueaux et al. Breast Cancer Research 2007 9:R33 doi:10.1186/bcr1681 |
||||||
